Global Maintenance/Controller Medicines for Asthma and COPD Market Growth 2026-2032

October 2026 | 181 pages | ID: G23A595C253EEN
LP Information

Abstracts

The global Maintenance/Controller Medicines for Asthma and COPD market size is predicted to grow from US$ 6430 million in 2025 to US$ 8607 million in 2032; it is expected to grow at a CAGR of 4.3% from 2026 to 2032.

Maintenance/controller medicines for asthma and COPD primarily include inhaled corticosteroids (ICS), long-acting ?2 agonists (LABA), long-acting muscarinic antagonists (LAMA), and combination therapies. Their development and production heavily rely on upstream suppliers of active pharmaceutical ingredients (APIs) and excipients, with raw materials mainly provided by multinational API manufacturers and specialized chemical producers. Leading pharmaceutical companies such as GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and Novartis hold strong R&D capabilities and significant market share in this sector.

Downstream customers mainly consist of hospitals, specialized clinics, retail pharmacy chains, and chronic disease management institutions, with particularly strong demand in Europe, the U.S., and Asia-Pacific. Given the long-term nature of asthma and COPD, patients have a high dependency on controller medicines, ensuring steady growth within the chronic disease therapeutics market. Looking ahead, innovations in inhalation devices and the adoption of personalized treatment regimens are expected to drive wider adoption of maintenance/controller medicines globally.

In 2024, the global average price of maintenance/controller medicines for asthma and COPD is approximately USD 19.5 per unit, with total sales reaching around 321 million units.

United States market for Maintenance/Controller Medicines for Asthma and COPD is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Maintenance/Controller Medicines for Asthma and COPD is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Maintenance/Controller Medicines for Asthma and COPD is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Maintenance/Controller Medicines for Asthma and COPD players cover AstraZeneca, Boehringer Ingelheim, The Menarini Group, Alfasigma, Gebro-Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

Report Scope

LP Information, Inc. (LPI) ' newest research report, the “Maintenance/Controller Medicines for Asthma and COPD Industry Forecast” looks at past sales and reviews total world Maintenance/Controller Medicines for Asthma and COPD sales in 2025, providing a comprehensive analysis by region and market sector of projected Maintenance/Controller Medicines for Asthma and COPD sales for 2026 through 2032. With Maintenance/Controller Medicines for Asthma and COPD sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Maintenance/Controller Medicines for Asthma and COPD industry.

This Insight Report provides a comprehensive analysis of the global Maintenance/Controller Medicines for Asthma and COPD landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Maintenance/Controller Medicines for Asthma and COPD portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Maintenance/Controller Medicines for Asthma and COPD market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Maintenance/Controller Medicines for Asthma and COPD and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Maintenance/Controller Medicines for Asthma and COPD.

This report presents a comprehensive overview, market shares, and growth opportunities of Maintenance/Controller Medicines for Asthma and COPD market by product type, application, key manufacturers and key regions and countries.

Market Segmentation

Segmentation by Type:

• Inhaled Corticosteroids (ICS)
• Long-Acting Muscarinic Antagonists (LAMA)
• Long-Acting Beta2 Agonists (LABA)
• LAMA-LABA
• ICS-LABA
• ICS-LABA-LAMA

Segmentation by Application:

• Hospital
• Clinic
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• AstraZeneca
• Boehringer Ingelheim
• The Menarini Group
• Alfasigma
• Gebro-Pharma
• Kohl Medical
• LEK-AM
• Polpharma
• Adamed Group
• STADA Arzneimittel
• GSK
• Chiesi Farmaceutici
• Teva Pharmaceutical
• Sumitomo Pharma
• Cipla
• Glenmark Pharmaceuticals
• Orion Corporation
• Bausch Health
• Viatris
• Novartis
• Covis Pharma
• Zentiva
• Lunan Better Pharmaceutical
• Jewim Pharmaceutical
• Shanghai Pharmaceuticals
• Zhejiang Xianjun Pharmaceutical
• Anhui Wellman Pharmaceutical
• Chia Tai Tianqing Pharmaceutical Group
• Nanchang Helioeast Technology

Key Questions Addressed in this Report

• What is the 10-year outlook for the global Maintenance/Controller Medicines for Asthma and COPD market?
• What factors are driving Maintenance/Controller Medicines for Asthma and COPD market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Maintenance/Controller Medicines for Asthma and COPD market opportunities vary by end market size?
• How does Maintenance/Controller Medicines for Asthma and COPD break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Maintenance/Controller Medicines for Asthma and COPD Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for Maintenance/Controller Medicines for Asthma and COPD by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for Maintenance/Controller Medicines for Asthma and COPD by Country/Region, 2021, 2025 & 2032
2.2 Maintenance/Controller Medicines for Asthma and COPD Segment by Type
  2.2.1 Inhaled Corticosteroids (ICS)
  2.2.2 Long-Acting Muscarinic Antagonists (LAMA)
  2.2.3 Long-Acting Beta2 Agonists (LABA)
  2.2.4 LAMA-LABA
  2.2.5 ICS-LABA
  2.2.6 ICS-LABA-LAMA
  2.2.7 Maintenance/Controller Medicines for Asthma and COPD Sales by Type
    2.2.7.1 Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Type (2021-2026)
    2.2.7.2 Global Maintenance/Controller Medicines for Asthma and COPD Revenue and Market Share by Type (2021-2026)
    2.2.7.3 Global Maintenance/Controller Medicines for Asthma and COPD Sale Price by Type (2021-2026)
2.3 Maintenance/Controller Medicines for Asthma and COPD Segment by Application
  2.3.1 Hospital
  2.3.2 Clinic
  2.3.3 Others
  2.3.4 Maintenance/Controller Medicines for Asthma and COPD Sales by Application
    2.3.4.1 Global Maintenance/Controller Medicines for Asthma and COPD Sale Market Share by Application (2021-2026)
    2.3.4.2 Global Maintenance/Controller Medicines for Asthma and COPD Revenue and Market Share by Application (2021-2026)
    2.3.4.3 Global Maintenance/Controller Medicines for Asthma and COPD Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Maintenance/Controller Medicines for Asthma and COPD Breakdown Data by Company
  3.1.1 Global Maintenance/Controller Medicines for Asthma and COPD Annual Sales by Company (2021-2026)
  3.1.2 Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Company (2021-2026)
3.2 Global Maintenance/Controller Medicines for Asthma and COPD Annual Revenue by Company (2021-2026)
  3.2.1 Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Company (2021-2026)
  3.2.2 Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Company (2021-2026)
3.3 Global Maintenance/Controller Medicines for Asthma and COPD Sale Price by Company
3.4 Key Manufacturers Maintenance/Controller Medicines for Asthma and COPD Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Maintenance/Controller Medicines for Asthma and COPD Product Location Distribution
  3.4.2 Players Maintenance/Controller Medicines for Asthma and COPD Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR MAINTENANCE/CONTROLLER MEDICINES FOR ASTHMA AND COPD BY GEOGRAPHIC REGION

4.1 World Historic Maintenance/Controller Medicines for Asthma and COPD Market Size by Geographic Region (2021-2026)
  4.1.1 Global Maintenance/Controller Medicines for Asthma and COPD Annual Sales by Geographic Region (2021-2026)
  4.1.2 Global Maintenance/Controller Medicines for Asthma and COPD Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Maintenance/Controller Medicines for Asthma and COPD Market Size by Country/Region (2021-2026)
  4.2.1 Global Maintenance/Controller Medicines for Asthma and COPD Annual Sales by Country/Region (2021-2026)
  4.2.2 Global Maintenance/Controller Medicines for Asthma and COPD Annual Revenue by Country/Region (2021-2026)
4.3 Americas Maintenance/Controller Medicines for Asthma and COPD Sales Growth
4.4 APAC Maintenance/Controller Medicines for Asthma and COPD Sales Growth
4.5 Europe Maintenance/Controller Medicines for Asthma and COPD Sales Growth
4.6 Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Sales Growth

5 AMERICAS

5.1 Americas Maintenance/Controller Medicines for Asthma and COPD Sales by Country
  5.1.1 Americas Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2021-2026)
  5.1.2 Americas Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2021-2026)
5.2 Americas Maintenance/Controller Medicines for Asthma and COPD Sales by Type (2021-2026)
5.3 Americas Maintenance/Controller Medicines for Asthma and COPD Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Maintenance/Controller Medicines for Asthma and COPD Sales by Region
  6.1.1 APAC Maintenance/Controller Medicines for Asthma and COPD Sales by Region (2021-2026)
  6.1.2 APAC Maintenance/Controller Medicines for Asthma and COPD Revenue by Region (2021-2026)
6.2 APAC Maintenance/Controller Medicines for Asthma and COPD Sales by Type (2021-2026)
6.3 APAC Maintenance/Controller Medicines for Asthma and COPD Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Maintenance/Controller Medicines for Asthma and COPD by Country
  7.1.1 Europe Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2021-2026)
  7.1.2 Europe Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2021-2026)
7.2 Europe Maintenance/Controller Medicines for Asthma and COPD Sales by Type (2021-2026)
7.3 Europe Maintenance/Controller Medicines for Asthma and COPD Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD by Country
  8.1.1 Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2021-2026)
  8.1.2 Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2021-2026)
8.2 Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Sales by Type (2021-2026)
8.3 Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Maintenance/Controller Medicines for Asthma and COPD
10.3 Manufacturing Process Analysis of Maintenance/Controller Medicines for Asthma and COPD
10.4 Industry Chain Structure of Maintenance/Controller Medicines for Asthma and COPD

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Maintenance/Controller Medicines for Asthma and COPD Distributors
11.3 Maintenance/Controller Medicines for Asthma and COPD Customer

12 WORLD FORECAST REVIEW FOR MAINTENANCE/CONTROLLER MEDICINES FOR ASTHMA AND COPD BY GEOGRAPHIC REGION

12.1 Global Maintenance/Controller Medicines for Asthma and COPD Market Size Forecast by Region
  12.1.1 Global Maintenance/Controller Medicines for Asthma and COPD Forecast by Region (2027-2032)
  12.1.2 Global Maintenance/Controller Medicines for Asthma and COPD Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Maintenance/Controller Medicines for Asthma and COPD Forecast by Type (2027-2032)
12.7 Global Maintenance/Controller Medicines for Asthma and COPD Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 AstraZeneca
  13.1.1 AstraZeneca Company Information
  13.1.2 AstraZeneca Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.1.3 AstraZeneca Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.1.4 AstraZeneca Main Business Overview
  13.1.5 AstraZeneca Latest Developments
13.2 Boehringer Ingelheim
  13.2.1 Boehringer Ingelheim Company Information
  13.2.2 Boehringer Ingelheim Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.2.3 Boehringer Ingelheim Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.2.4 Boehringer Ingelheim Main Business Overview
  13.2.5 Boehringer Ingelheim Latest Developments
13.3 The Menarini Group
  13.3.1 The Menarini Group Company Information
  13.3.2 The Menarini Group Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.3.3 The Menarini Group Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.3.4 The Menarini Group Main Business Overview
  13.3.5 The Menarini Group Latest Developments
13.4 Alfasigma
  13.4.1 Alfasigma Company Information
  13.4.2 Alfasigma Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.4.3 Alfasigma Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.4.4 Alfasigma Main Business Overview
  13.4.5 Alfasigma Latest Developments
13.5 Gebro-Pharma
  13.5.1 Gebro-Pharma Company Information
  13.5.2 Gebro-Pharma Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.5.3 Gebro-Pharma Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.5.4 Gebro-Pharma Main Business Overview
  13.5.5 Gebro-Pharma Latest Developments
13.6 Kohl Medical
  13.6.1 Kohl Medical Company Information
  13.6.2 Kohl Medical Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.6.3 Kohl Medical Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.6.4 Kohl Medical Main Business Overview
  13.6.5 Kohl Medical Latest Developments
13.7 LEK-AM
  13.7.1 LEK-AM Company Information
  13.7.2 LEK-AM Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.7.3 LEK-AM Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.7.4 LEK-AM Main Business Overview
  13.7.5 LEK-AM Latest Developments
13.8 Polpharma
  13.8.1 Polpharma Company Information
  13.8.2 Polpharma Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.8.3 Polpharma Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.8.4 Polpharma Main Business Overview
  13.8.5 Polpharma Latest Developments
13.9 Adamed Group
  13.9.1 Adamed Group Company Information
  13.9.2 Adamed Group Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.9.3 Adamed Group Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.9.4 Adamed Group Main Business Overview
  13.9.5 Adamed Group Latest Developments
13.10 STADA Arzneimittel
  13.10.1 STADA Arzneimittel Company Information
  13.10.2 STADA Arzneimittel Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.10.3 STADA Arzneimittel Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.10.4 STADA Arzneimittel Main Business Overview
  13.10.5 STADA Arzneimittel Latest Developments
13.11 GSK
  13.11.1 GSK Company Information
  13.11.2 GSK Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.11.3 GSK Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.11.4 GSK Main Business Overview
  13.11.5 GSK Latest Developments
13.12 Chiesi Farmaceutici
  13.12.1 Chiesi Farmaceutici Company Information
  13.12.2 Chiesi Farmaceutici Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.12.3 Chiesi Farmaceutici Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.12.4 Chiesi Farmaceutici Main Business Overview
  13.12.5 Chiesi Farmaceutici Latest Developments
13.13 Teva Pharmaceutical
  13.13.1 Teva Pharmaceutical Company Information
  13.13.2 Teva Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.13.3 Teva Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.13.4 Teva Pharmaceutical Main Business Overview
  13.13.5 Teva Pharmaceutical Latest Developments
13.14 Sumitomo Pharma
  13.14.1 Sumitomo Pharma Company Information
  13.14.2 Sumitomo Pharma Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.14.3 Sumitomo Pharma Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.14.4 Sumitomo Pharma Main Business Overview
  13.14.5 Sumitomo Pharma Latest Developments
13.15 Cipla
  13.15.1 Cipla Company Information
  13.15.2 Cipla Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.15.3 Cipla Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.15.4 Cipla Main Business Overview
  13.15.5 Cipla Latest Developments
13.16 Glenmark Pharmaceuticals
  13.16.1 Glenmark Pharmaceuticals Company Information
  13.16.2 Glenmark Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.16.3 Glenmark Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.16.4 Glenmark Pharmaceuticals Main Business Overview
  13.16.5 Glenmark Pharmaceuticals Latest Developments
13.17 Orion Corporation
  13.17.1 Orion Corporation Company Information
  13.17.2 Orion Corporation Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.17.3 Orion Corporation Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.17.4 Orion Corporation Main Business Overview
  13.17.5 Orion Corporation Latest Developments
13.18 Bausch Health
  13.18.1 Bausch Health Company Information
  13.18.2 Bausch Health Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.18.3 Bausch Health Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.18.4 Bausch Health Main Business Overview
  13.18.5 Bausch Health Latest Developments
13.19 Viatris
  13.19.1 Viatris Company Information
  13.19.2 Viatris Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.19.3 Viatris Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.19.4 Viatris Main Business Overview
  13.19.5 Viatris Latest Developments
13.20 Novartis
  13.20.1 Novartis Company Information
  13.20.2 Novartis Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.20.3 Novartis Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.20.4 Novartis Main Business Overview
  13.20.5 Novartis Latest Developments
13.21 Covis Pharma
  13.21.1 Covis Pharma Company Information
  13.21.2 Covis Pharma Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.21.3 Covis Pharma Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.21.4 Covis Pharma Main Business Overview
  13.21.5 Covis Pharma Latest Developments
13.22 Zentiva
  13.22.1 Zentiva Company Information
  13.22.2 Zentiva Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.22.3 Zentiva Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.22.4 Zentiva Main Business Overview
  13.22.5 Zentiva Latest Developments
13.23 Lunan Better Pharmaceutical
  13.23.1 Lunan Better Pharmaceutical Company Information
  13.23.2 Lunan Better Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.23.3 Lunan Better Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.23.4 Lunan Better Pharmaceutical Main Business Overview
  13.23.5 Lunan Better Pharmaceutical Latest Developments
13.24 Jewim Pharmaceutical
  13.24.1 Jewim Pharmaceutical Company Information
  13.24.2 Jewim Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.24.3 Jewim Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.24.4 Jewim Pharmaceutical Main Business Overview
  13.24.5 Jewim Pharmaceutical Latest Developments
13.25 Shanghai Pharmaceuticals
  13.25.1 Shanghai Pharmaceuticals Company Information
  13.25.2 Shanghai Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.25.3 Shanghai Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.25.4 Shanghai Pharmaceuticals Main Business Overview
  13.25.5 Shanghai Pharmaceuticals Latest Developments
13.26 Zhejiang Xianjun Pharmaceutical
  13.26.1 Zhejiang Xianjun Pharmaceutical Company Information
  13.26.2 Zhejiang Xianjun Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.26.3 Zhejiang Xianjun Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.26.4 Zhejiang Xianjun Pharmaceutical Main Business Overview
  13.26.5 Zhejiang Xianjun Pharmaceutical Latest Developments
13.27 Anhui Wellman Pharmaceutical
  13.27.1 Anhui Wellman Pharmaceutical Company Information
  13.27.2 Anhui Wellman Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.27.3 Anhui Wellman Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.27.4 Anhui Wellman Pharmaceutical Main Business Overview
  13.27.5 Anhui Wellman Pharmaceutical Latest Developments
13.28 Chia Tai Tianqing Pharmaceutical Group
  13.28.1 Chia Tai Tianqing Pharmaceutical Group Company Information
  13.28.2 Chia Tai Tianqing Pharmaceutical Group Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.28.3 Chia Tai Tianqing Pharmaceutical Group Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.28.4 Chia Tai Tianqing Pharmaceutical Group Main Business Overview
  13.28.5 Chia Tai Tianqing Pharmaceutical Group Latest Developments
13.29 Nanchang Helioeast Technology
  13.29.1 Nanchang Helioeast Technology Company Information
  13.29.2 Nanchang Helioeast Technology Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
  13.29.3 Nanchang Helioeast Technology Maintenance/Controller Medicines for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
  13.29.4 Nanchang Helioeast Technology Main Business Overview
  13.29.5 Nanchang Helioeast Technology Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Maintenance/Controller Medicines for Asthma and COPD Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Maintenance/Controller Medicines for Asthma and COPD Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Inhaled Corticosteroids (ICS)
Table 4. Major Players of Long-Acting Muscarinic Antagonists (LAMA)
Table 5. Major Players of Long-Acting Beta2 Agonists (LABA)
Table 6. Major Players of LAMA-LABA
Table 7. Major Players of ICS-LABA
Table 8. Major Players of ICS-LABA-LAMA
Table 9. Global Maintenance/Controller Medicines for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 10. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Type (2021-2026)
Table 11. Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Type (2021-2026) & ($ million)
Table 12. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Type (2021-2026)
Table 13. Global Maintenance/Controller Medicines for Asthma and COPD Sale Price by Type (2021-2026) & (US$/Unit)
Table 14. Global Maintenance/Controller Medicines for Asthma and COPD Sale by Application (2021-2026) & (K Units)
Table 15. Global Maintenance/Controller Medicines for Asthma and COPD Sale Market Share by Application (2021-2026)
Table 16. Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Application (2021-2026) & ($ million)
Table 17. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Application (2021-2026)
Table 18. Global Maintenance/Controller Medicines for Asthma and COPD Sale Price by Application (2021-2026) & (US$/Unit)
Table 19. Global Maintenance/Controller Medicines for Asthma and COPD Sales by Company (2021-2026) & (K Units)
Table 20. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Company (2021-2026)
Table 21. Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Company (2021-2026) & ($ millions)
Table 22. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Company (2021-2026)
Table 23. Global Maintenance/Controller Medicines for Asthma and COPD Sale Price by Company (2021-2026) & (US$/Unit)
Table 24. Key Manufacturers Maintenance/Controller Medicines for Asthma and COPD Producing Area Distribution and Sales Area
Table 25. Players Maintenance/Controller Medicines for Asthma and COPD Products Offered
Table 26. Maintenance/Controller Medicines for Asthma and COPD Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Maintenance/Controller Medicines for Asthma and COPD Sales by Geographic Region (2021-2026) & (K Units)
Table 30. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share Geographic Region (2021-2026)
Table 31. Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Geographic Region (2021-2026) & ($ millions)
Table 32. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Geographic Region (2021-2026)
Table 33. Global Maintenance/Controller Medicines for Asthma and COPD Sales by Country/Region (2021-2026) & (K Units)
Table 34. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Country/Region (2021-2026)
Table 35. Global Maintenance/Controller Medicines for Asthma and COPD Revenue by Country/Region (2021-2026) & ($ millions)
Table 36. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Country/Region (2021-2026)
Table 37. Americas Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2021-2026) & (K Units)
Table 38. Americas Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Country (2021-2026)
Table 39. Americas Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2021-2026) & ($ millions)
Table 40. Americas Maintenance/Controller Medicines for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 41. Americas Maintenance/Controller Medicines for Asthma and COPD Sales by Application (2021-2026) & (K Units)
Table 42. APAC Maintenance/Controller Medicines for Asthma and COPD Sales by Region (2021-2026) & (K Units)
Table 43. APAC Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Region (2021-2026)
Table 44. APAC Maintenance/Controller Medicines for Asthma and COPD Revenue by Region (2021-2026) & ($ millions)
Table 45. APAC Maintenance/Controller Medicines for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 46. APAC Maintenance/Controller Medicines for Asthma and COPD Sales by Application (2021-2026) & (K Units)
Table 47. Europe Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2021-2026) & (K Units)
Table 48. Europe Maintenance/Controller Medicines for Asthma and COPD Revenue by Country (2021-2026) & ($ millions)
Table 49. Europe Maintenance/Controller Medicines for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 50. Europe Maintenance/Controller Medicines for Asthma and COPD Sales by Application (2021-2026) & (K Units)
Table 51. Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Sales by Country (2021-2026) & (K Units)
Table 52. Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Country (2021-2026)
Table 53. Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 54. Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Sales by Application (2021-2026) & (K Units)
Table 55. Key Market Drivers & Growth Opportunities of Maintenance/Controller Medicines for Asthma and COPD
Table 56. Key Market Challenges & Risks of Maintenance/Controller Medicines for Asthma and COPD
Table 57. Key Industry Trends of Maintenance/Controller Medicines for Asthma and COPD
Table 58. Maintenance/Controller Medicines for Asthma and COPD Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Maintenance/Controller Medicines for Asthma and COPD Distributors List
Table 61. Maintenance/Controller Medicines for Asthma and COPD Customer List
Table 62. Global Maintenance/Controller Medicines for Asthma and COPD Sales Forecast by Region (2027-2032) & (K Units)
Table 63. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Americas Maintenance/Controller Medicines for Asthma and COPD Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Americas Maintenance/Controller Medicines for Asthma and COPD Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. APAC Maintenance/Controller Medicines for Asthma and COPD Sales Forecast by Region (2027-2032) & (K Units)
Table 67. APAC Maintenance/Controller Medicines for Asthma and COPD Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 68. Europe Maintenance/Controller Medicines for Asthma and COPD Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Europe Maintenance/Controller Medicines for Asthma and COPD Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Sales Forecast by Country (2027-2032) & (K Units)
Table 71. Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. Global Maintenance/Controller Medicines for Asthma and COPD Sales Forecast by Type (2027-2032) & (K Units)
Table 73. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Forecast by Type (2027-2032) & ($ millions)
Table 74. Global Maintenance/Controller Medicines for Asthma and COPD Sales Forecast by Application (2027-2032) & (K Units)
Table 75. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Forecast by Application (2027-2032) & ($ millions)
Table 76. AstraZeneca Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 77. AstraZeneca Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 78. AstraZeneca Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 79. AstraZeneca Main Business
Table 80. AstraZeneca Latest Developments
Table 81. Boehringer Ingelheim Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 82. Boehringer Ingelheim Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 83. Boehringer Ingelheim Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. Boehringer Ingelheim Main Business
Table 85. Boehringer Ingelheim Latest Developments
Table 86. The Menarini Group Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 87. The Menarini Group Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 88. The Menarini Group Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. The Menarini Group Main Business
Table 90. The Menarini Group Latest Developments
Table 91. Alfasigma Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 92. Alfasigma Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 93. Alfasigma Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Alfasigma Main Business
Table 95. Alfasigma Latest Developments
Table 96. Gebro-Pharma Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 97. Gebro-Pharma Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 98. Gebro-Pharma Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Gebro-Pharma Main Business
Table 100. Gebro-Pharma Latest Developments
Table 101. Kohl Medical Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 102. Kohl Medical Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 103. Kohl Medical Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Kohl Medical Main Business
Table 105. Kohl Medical Latest Developments
Table 106. LEK-AM Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 107. LEK-AM Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 108. LEK-AM Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. LEK-AM Main Business
Table 110. LEK-AM Latest Developments
Table 111. Polpharma Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 112. Polpharma Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 113. Polpharma Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. Polpharma Main Business
Table 115. Polpharma Latest Developments
Table 116. Adamed Group Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 117. Adamed Group Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 118. Adamed Group Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. Adamed Group Main Business
Table 120. Adamed Group Latest Developments
Table 121. STADA Arzneimittel Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 122. STADA Arzneimittel Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 123. STADA Arzneimittel Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. STADA Arzneimittel Main Business
Table 125. STADA Arzneimittel Latest Developments
Table 126. GSK Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 127. GSK Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 128. GSK Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. GSK Main Business
Table 130. GSK Latest Developments
Table 131. Chiesi Farmaceutici Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 132. Chiesi Farmaceutici Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 133. Chiesi Farmaceutici Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Chiesi Farmaceutici Main Business
Table 135. Chiesi Farmaceutici Latest Developments
Table 136. Teva Pharmaceutical Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 137. Teva Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 138. Teva Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. Teva Pharmaceutical Main Business
Table 140. Teva Pharmaceutical Latest Developments
Table 141. Sumitomo Pharma Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 142. Sumitomo Pharma Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 143. Sumitomo Pharma Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 144. Sumitomo Pharma Main Business
Table 145. Sumitomo Pharma Latest Developments
Table 146. Cipla Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 147. Cipla Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 148. Cipla Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 149. Cipla Main Business
Table 150. Cipla Latest Developments
Table 151. Glenmark Pharmaceuticals Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 152. Glenmark Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 153. Glenmark Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 154. Glenmark Pharmaceuticals Main Business
Table 155. Glenmark Pharmaceuticals Latest Developments
Table 156. Orion Corporation Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 157. Orion Corporation Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 158. Orion Corporation Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 159. Orion Corporation Main Business
Table 160. Orion Corporation Latest Developments
Table 161. Bausch Health Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 162. Bausch Health Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 163. Bausch Health Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 164. Bausch Health Main Business
Table 165. Bausch Health Latest Developments
Table 166. Viatris Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 167. Viatris Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 168. Viatris Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 169. Viatris Main Business
Table 170. Viatris Latest Developments
Table 171. Novartis Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 172. Novartis Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 173. Novartis Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 174. Novartis Main Business
Table 175. Novartis Latest Developments
Table 176. Covis Pharma Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 177. Covis Pharma Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 178. Covis Pharma Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 179. Covis Pharma Main Business
Table 180. Covis Pharma Latest Developments
Table 181. Zentiva Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 182. Zentiva Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 183. Zentiva Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 184. Zentiva Main Business
Table 185. Zentiva Latest Developments
Table 186. Lunan Better Pharmaceutical Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 187. Lunan Better Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 188. Lunan Better Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 189. Lunan Better Pharmaceutical Main Business
Table 190. Lunan Better Pharmaceutical Latest Developments
Table 191. Jewim Pharmaceutical Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 192. Jewim Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 193. Jewim Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 194. Jewim Pharmaceutical Main Business
Table 195. Jewim Pharmaceutical Latest Developments
Table 196. Shanghai Pharmaceuticals Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 197. Shanghai Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 198. Shanghai Pharmaceuticals Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 199. Shanghai Pharmaceuticals Main Business
Table 200. Shanghai Pharmaceuticals Latest Developments
Table 201. Zhejiang Xianjun Pharmaceutical Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 202. Zhejiang Xianjun Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 203. Zhejiang Xianjun Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 204. Zhejiang Xianjun Pharmaceutical Main Business
Table 205. Zhejiang Xianjun Pharmaceutical Latest Developments
Table 206. Anhui Wellman Pharmaceutical Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 207. Anhui Wellman Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 208. Anhui Wellman Pharmaceutical Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 209. Anhui Wellman Pharmaceutical Main Business
Table 210. Anhui Wellman Pharmaceutical Latest Developments
Table 211. Chia Tai Tianqing Pharmaceutical Group Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 212. Chia Tai Tianqing Pharmaceutical Group Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 213. Chia Tai Tianqing Pharmaceutical Group Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 214. Chia Tai Tianqing Pharmaceutical Group Main Business
Table 215. Chia Tai Tianqing Pharmaceutical Group Latest Developments
Table 216. Nanchang Helioeast Technology Basic Information, Maintenance/Controller Medicines for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 217. Nanchang Helioeast Technology Maintenance/Controller Medicines for Asthma and COPD Product Portfolios and Specifications
Table 218. Nanchang Helioeast Technology Maintenance/Controller Medicines for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 219. Nanchang Helioeast Technology Main Business
Table 220. Nanchang Helioeast Technology Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Maintenance/Controller Medicines for Asthma and COPD
Figure 2. Maintenance/Controller Medicines for Asthma and COPD Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Maintenance/Controller Medicines for Asthma and COPD Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Maintenance/Controller Medicines for Asthma and COPD Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Country/Region (2025)
Figure 10. Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Inhaled Corticosteroids (ICS)
Figure 12. Product Picture of Long-Acting Muscarinic Antagonists (LAMA)
Figure 13. Product Picture of Long-Acting Beta2 Agonists (LABA)
Figure 14. Product Picture of LAMA-LABA
Figure 15. Product Picture of ICS-LABA
Figure 16. Product Picture of ICS-LABA-LAMA
Figure 17. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Type in 2026
Figure 18. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Type (2021-2026)
Figure 19. Maintenance/Controller Medicines for Asthma and COPD Consumed in Hospital
Figure 20. Global Maintenance/Controller Medicines for Asthma and COPD Market: Hospital (2021-2026) & (K Units)
Figure 21. Maintenance/Controller Medicines for Asthma and COPD Consumed in Clinic
Figure 22. Global Maintenance/Controller Medicines for Asthma and COPD Market: Clinic (2021-2026) & (K Units)
Figure 23. Maintenance/Controller Medicines for Asthma and COPD Consumed in Others
Figure 24. Global Maintenance/Controller Medicines for Asthma and COPD Market: Others (2021-2026) & (K Units)
Figure 25. Global Maintenance/Controller Medicines for Asthma and COPD Sale Market Share by Application (2025)
Figure 26. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Application in 2026
Figure 27. Maintenance/Controller Medicines for Asthma and COPD Sales by Company in 2026 (K Units)
Figure 28. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Company in 2026
Figure 29. Maintenance/Controller Medicines for Asthma and COPD Revenue by Company in 2026 ($ millions)
Figure 30. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Company in 2026
Figure 31. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Maintenance/Controller Medicines for Asthma and COPD Sales 2021-2026 (K Units)
Figure 34. Americas Maintenance/Controller Medicines for Asthma and COPD Revenue 2021-2026 ($ millions)
Figure 35. APAC Maintenance/Controller Medicines for Asthma and COPD Sales 2021-2026 (K Units)
Figure 36. APAC Maintenance/Controller Medicines for Asthma and COPD Revenue 2021-2026 ($ millions)
Figure 37. Europe Maintenance/Controller Medicines for Asthma and COPD Sales 2021-2026 (K Units)
Figure 38. Europe Maintenance/Controller Medicines for Asthma and COPD Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Revenue 2021-2026 ($ millions)
Figure 41. Americas Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Country in 2026
Figure 42. Americas Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Country (2021-2026)
Figure 43. Americas Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Type (2021-2026)
Figure 44. Americas Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Application (2021-2026)
Figure 45. United States Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Region in 2026
Figure 50. APAC Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Region (2021-2026)
Figure 51. APAC Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Type (2021-2026)
Figure 52. APAC Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Application (2021-2026)
Figure 53. China Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 57. India Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Country in 2026
Figure 61. Europe Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share by Country (2021-2026)
Figure 62. Europe Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Type (2021-2026)
Figure 63. Europe Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Application (2021-2026)
Figure 64. Germany Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 65. France Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Maintenance/Controller Medicines for Asthma and COPD Sales Market Share by Application (2021-2026)
Figure 72. Egypt Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Maintenance/Controller Medicines for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Maintenance/Controller Medicines for Asthma and COPD in 2026
Figure 78. Manufacturing Process Analysis of Maintenance/Controller Medicines for Asthma and COPD
Figure 79. Industry Chain Structure of Maintenance/Controller Medicines for Asthma and COPD
Figure 80. Channels of Distribution
Figure 81. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Forecast by Region (2027-2032)
Figure 82. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Maintenance/Controller Medicines for Asthma and COPD Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Maintenance/Controller Medicines for Asthma and COPD Revenue Market Share Forecast by Application (2027-2032)